Novartis has claimed accelerated approval in the US for Vanrafia, one of a trio of drugs it hopes will revolutionise the treatment of IgA nephropathy. Otsuka is hoping to file for approval of its ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

Expanding Global Support: IgA Nephropathy Foundation Launches Go Global Network to Connect and Empower IgAN Patients Worldwide. By expanding our network to Canada, we are building a stronger ...

Novartis Trading Up 1.0 % Shares of Novartis stock opened at $110.69 on Friday. Novartis has a fifty-two week low of $94.72 and a fifty-two week high of $120.92. The company has a debt-to-equity ...

regarding the use of the company’s drug Filspari in IgA nephropathy (IgAN). The KOL’s view suggests that Filspari’s market adoption may not be significantly affected by the recently approved ...

Novartis AG NVS, a Swiss pharma giant, is scheduled to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $12.86 billion, while the same ...

"European price controls and austerity measures reduce the attractiveness of its markets," Novartis CEO Vas Narasimhan and Sanofi CEO Paul Hudson wrote. "Against a backdrop of waning European ...

As Iga Świątek prepares for a challenging draw at the upcoming Mutua Madrid Open, her coach, Wim Fissette, has shed light on the team's focus on improving a key component of her game ...